

**LATHAM & WATKINS** LLP

FIRM / AFFILIATE OFFICES

Beijing	Moscow
Boston	Munich
Brussels	New York
Century City	Orange County
Chicago	Paris
Dubai	Riyadh
Düsseldorf	San Diego
Frankfurt	San Francisco
Hamburg	Seoul
Hong Kong	Shanghai
Houston	Silicon Valley
London	Singapore
Los Angeles	Tokyo
Madrid	Washington, D.C.
Milan	

January 25, 2021

**Via EDGAR**

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

Attn: Eric Atallah  
Mary Mast  
Courtney Lindsay  
Joe McCann

**Re: Ortho Clinical Diagnostics Holdings plc  
Registration Statement on Form S-1 (File No. 333-251875)**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, we attach the requests of our client, Ortho Clinical Diagnostics Holdings plc (the “**Company**”), and of the underwriters that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-251875) be accelerated to 3:00 p.m. Washington D.C. time on January 27, 2021, or as soon as practicable thereafter. We ask, however, that the Securities and Exchange Commission staff not accelerate such effective date until we speak with you on that date.

Please direct any questions or comments regarding the foregoing to me at (202) 637-1028 or my colleague, Jason M. Licht, at (202) 637-2258.

Very truly yours,

/s/ Patrick H. Shannon

---

Patrick H. Shannon  
of LATHAM & WATKINS LLP

cc: Jason M. Licht, Latham & Watkins LLP

**Ortho Clinical Diagnostics Holdings plc**  
1001 Route 202  
Raritan, New Jersey 08869

January 25, 2021

**Via EDGAR**

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

Attn: Eric Atallah  
Mary Mast  
Courtney Lindsay  
Joe McCann

**Re: Ortho Clinical Diagnostics Holdings plc  
Registration Statement on Form S-1 (File No. 333-251875)**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Ortho Clinical Diagnostics Holdings plc (the "**Company**") hereby respectfully requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-251875) be accelerated by the Securities and Exchange Commission to 3:00 p.m. Washington D.C. time on January 27, 2021 or as soon as practicable thereafter.

\* \* \* \*

The Company requests that we be notified of such effectiveness by a telephone call to Patrick Shannon of Latham & Watkins LLP at (202) 637-1028 or to Jason Licht of Latham & Watkins LLP at (202) 637-2258 and that such effectiveness also be confirmed in writing.

Very truly yours,

Ortho Clinical Diagnostics Holdings plc

/s/ Michael A. Schlesinger

Name: Michael A. Schlesinger

Title: Executive Vice President, General Counsel and  
Secretary

cc: Chris Smith, Chief Executive Officer, Ortho Clinical Diagnostics Holdings plc  
Patrick H. Shannon, Latham & Watkins LLP  
Jason M. Licht, Latham & Watkins LLP

**J.P. Morgan Securities LLC  
BofA Securities, Inc.  
Goldman Sachs & Co. LLC**  
As representatives of the several Underwriters

c/o  
J.P. Morgan Securities LLC  
383 Madison Avenue  
New York, New York 10179

BofA Securities, Inc.  
One Bryant Park  
New York, New York 10036

and,  
Goldman Sachs & Co. LLC  
200 West Street  
New York, New York 10282

VIA EDGAR

January 25, 2021

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

Re: Ortho Clinical Diagnostics Holdings plc (the "Company")  
Registration Statement on Form S-1 (File No. 333-251875)

Ladies and Gentlemen:

Pursuant to Rule 461 of the Rules and Regulations of the U.S. Securities and Exchange Commission (the "Commission") under the Securities Act of 1933, as amended (the "Securities Act"), the undersigned as representatives of the several underwriters (collectively, the "Underwriters") of the proposed public offering of the Company's common stock, hereby join the Company's request that the effective date of the above-referenced Registration Statement be accelerated so that the above-referenced Registration Statement will be declared effective at 3:00 p.m., Washington, D.C. time, on January 27, 2021, or as soon thereafter as is practicable.

Pursuant to Rule 460 of the Rules and Regulations of the Commission under the Securities Act, we wish to advise you that we have effected the following distribution of each of the Company's Preliminary Prospectus dated January 19, 2021, through the date hereof:

Preliminary Prospectus dated January 19, 2021:

Approximately 3,786 copies to prospective underwriters, institutional investors, dealers and others.

The undersigned advise that they have complied and will continue to comply, and that they have been informed by the participating underwriters and dealers that they have complied with and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

*[Remainder of Page Intentionally Left Blank]*

Signature

Title

/s/ David Ke Executive Director at J.P. Morgan Securities LLC  
David Ke

/s/ Michele A.H. Allong Authorized Signatory at BofA Securities, Inc.  
Michele A.H. Allong

/s/ Elizabeth Wood Managing Director at Goldman Sachs & Co. LLC  
Elizabeth Wood

*[Signature Page to Acceleration Request by Underwriters]*